Amneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $610 million versus the consensus estimate of $579.84 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.31 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.